Are SGP insiders buying or selling?

In the last 90 days, SpyGlass (SGP) had 0 insider transactions. Track every executive trade, dollar amount, and date.

Which hedge funds own SGP?

See every hedge fund and asset manager holding SpyGlass (SGP).

How much of SGP trades in dark pools?

0.083M SGP shares ($2M notional) traded off-exchange last week — block trades typical of institutional flow.

SpyGlass (SGP) — 86.6% Short — Squeeze Watch

$21.62

+0.80 (+3.84%)

Weekly Expected Move ±13.4%

$15 $18 $20 $23 $26

NASDAQ · Healthcare · Biotechnology · Alpha Radar Buy · Power 60 · $722.8M mcap · 14M float · 0.789% daily turnover · Short 84% of daily vol

Smart Money Score

Watch 25

Insider—

Congress—

ETF Holdings—

Key Statistics

Market Cap$722.8M

52W Range17.06-32.44

Volume69,463

Avg Volume110,137

Beta-0.96

Dividend—

Analyst Ratings

No analyst coverage

Company Info

CEOPatrick H. Mooney

Employees65

SectorHealthcare

IndustryBiotechnology

IPO Date2026-02-06

Websitespyglasspharma.com

27061 Aliso Creek Road
Aliso Viejo, CA 92656
US

1 949 535 0588

About SpyGlass Pharma, Inc. Common Stock

SpyGlass Pharma, Inc. is an advanced biopharmaceutical company dedicated to developing innovative therapeutic approaches for individuals suffering from chronic eye conditions. Its flagship investigational product, the Bimatoprost Drug Pad-IOL System (BIM-IOL System), is engineered for implantation during standard cataract removal procedures with the aim of reducing elevated intraocular pressure (IOP) in patients afflicted with either open-angle glaucoma (OAG) or ocular hypertension (OHT). Co-founded in January 2019 by Malik Y. Kahook and Glenn Sussman, the company maintains its headquarters in Aliso Viejo, CA.

Latest News